An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies

참고문헌 (60)

1. Cassidy, J. T., "Human serum immunoglobulin concentrations : prevalence of immunoglobulin deficiencies", J. Allergy Clin. Immunol, 55, pp.35~48 (1975)
2. Gonzalez-Quintela, A., "Serum levels of immunoglobulins(IgG, IgA, IgM)in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities", Clin. Exp. Immunol, 151, pp.42~50 (2008)
3. Iwasaki, A., "Control of adaptive immunity by the innate immune system", Nat. Immunol, 16, pp.343~353 (2015)
4. Panda, S., "Natural antibodies bridge innate and adaptive immunity", J. Immunol, 194, pp.13~20 (2015)
5. Adkins, B., "Neonatal adaptive immunity comes of age", Nat. Rev. Immunol, 4, pp.553~564 (2004)
6. Roopenian, D. C., "FcRn: the neonatal Fc receptor comes of age", Nat. Rev. Immunol, 7, pp.715~725 (2007)
7. Ward, E. S., "Targeting FcRn to generate antibody-based therapeutics", Trends Pharmacol. Sci, 39, pp.892~904 (2018)
8. Ko, S., "Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering", BioDrugs, 35, pp.147~157 (2021)
9. Burmeister, W. P., "Crystal structure of the complex of rat neonatal Fc receptor with Fc", Nature, 372, pp.379~383 (1994)
10. Prabhat, P., "Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy", Proc. Natl Acad. Sci. USA, 104, pp.5889~5894 (2007)
11. Weflen, A. W., "Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules", J. Mol. Cell Biol, 24, pp.2398~2405 (2013)
12. Grevys, A., "A human endothelial cell-based recycling assay for screening of FcRn targeted molecules", Nat. Commun, 9, pp.621~ (2018)
13. Martin, W. L., "Crystal structure at 2.8 A of an FcRn", heterodimeric Fc complex: mechanism of pH-dependent binding, 2001, pp.7, 867~877
14. Vaughn, D. E., "Structural basis of pH-dependent antibody binding by the neonatal Fc receptor", Structure, 6, pp.63~73 (1998)
15. Shields, R. L., "High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R", J. Biol. Chem, 276, pp.6591~6604 (2001)
16. Zalevsky, J., "Enhanced antibody half-life improves in vivo activity", Nat. Biotechnol, 28, pp.157~159 (2010)
17. Park, H. I., "The highly evolvable antibody Fc domain", Trends Biotechnol, 34, pp.895~908 (2016)
18. 정상택, "Tailoring Immunoglobulin Fc for Highly Potent and Serum-stable Therapeutic Antibodies", Biotechnology and Bioprocess Engineering, 18(4), pp.625~636 (2013), 한국생물공학회
19. Dall’Acqua, W. F., "Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor(FcRn)", J. Biol. Chem, 281, pp.23514~23524 (2006)
20. Levin, M. J., "LB5. PROVENT: phase 3 study of efficacy and safety of AZD7442(Tixagevimab", Cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults, 2021, pp.8, S810~S810
21. Domachowske, J. B., "Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants", J. Pediatr. Infect. Dis, 37, pp.886~892 (2018)
22. Kulasekararaj, A. G., "Ravulizumab(ALXN1210)vs eculizumab in C5-inhibitorexperienced adult patients with PNH : the 302 study", Blood, 133, pp.540~549 (2019)
23. Pinto, D., "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARSCoV antibody", Nature, 583, pp.290~295 (2020)
24. "An EUA for sotrovimab for treatment of COVID-19", Med. Lett. Drugs Ther, 63, pp.97~xx98 (2021)
25. Booth, B. J., "Extending human IgG half-life using structure-guided design", MAbs, 10, pp.1098~1110 (2018)
26. Mackness, B. C., "Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life", MAbs, 11, pp.1276~1288 (2019)
27. Lee, C. H., "An engineered human Fc domain that behaves like a pHtoggle switch for ultra-long circulation persistence", Nat. Commun, 10, pp.5031~ (2019)
28. Deng, R., "Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?", MAbs, 3, pp.61~66 (2011)
29. Dong, J. Q., "Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction", Clin. Pharmacokinet, 50, pp.131~142 (2011)
30. Ling, J., "Interspecies scaling of therapeutic monoclonal antibodies : initial look", J. Clin. Pharmacol, 49, pp.1382~1402 (2009)
31. Pyzik, M., "The neonatal Fc receptor (FcRn): a misnomer?", Front. immunol, 10, pp.1540~ (2019)
32. Jo, M., "Escherichia coli inner membrane display system for high-throughput screening of dimeric proteins", Biotechnol. Bioeng, 115, pp.2849~2858 (2018)
33. Jung, S. T., "Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity", ACS Chem. Biol, 8, pp.368~375 (2013)
34. Jung, S. T., "Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells", Proc. Natl Acad. Sci. USA, 107, pp.604~609 (2010)
35. Abdiche, Y. N., "The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity", MAbs, 7, pp.331~343 (2015)
36. Yeung, Y. A., "Engineering human IgG1 affinity to human neonatal Fc receptor : impact of affinity improvement on pharmacokinetics in primates", J. Immunol, 182, pp.7663~7671 (2009)
37. Ober, R. J., "Differences in promiscuity for antibody-FcRn interactions across species : implications for therapeutic antibodies", Int. Immunol, 13, pp.1551~1559 (2001)
38. Latvala, S., "Distribution of FcRn across species and tissues", J. Histochem. Cytochem, 65, pp.321~333 (2017)
39. Cole, M. F., "W. H. Immunoglobulins A, G, and M in serum and in some secretions of monkeys (Macaca fascicularis syn. irus)", Infect. Immun, 13, pp.1354~1359 (1976)
40. Hinton, P. R., "An engineered human IgG1 antibody with longer serum halflife", J. Immunol, 176, pp.346~356 (2006)
41. 정태현, "Boosting therapeutic potency of antibodies by taming Fc domain functions", Experimental and Molecular Medicine, 51, pp.1~9 (2019), 생화학분자생물학회[DOI]
42. Borrok, M. J., "An"Fc-silenced"IgG1 format with extended half-life designed for improved stability", J. Pharm. Sci, 106, pp.1008~1017 (2017)
43. Wang, Y., "CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity", Oncol. Lett, 14, pp.2961~2969 (2017)
44. Strohl, W. R., "Optimization of Fc-mediated effector functions of monoclonal antibodies", Curr. Opin. Biotechnol, 20, pp.685~691 (2009)
45. Pollreisz, A., "Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro", Br. J. Dermatol, 159, pp.578~584 (2008)
46. Kontermann, R. E., "Bispecific antibodies", Drug Discov, 20, pp.838~847 (2015)
47. Canfield, S. M., "The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region", J. Exp. Med, 173, pp.1483~1491 (1991)
48. Lo, M., "Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice", J. Biol. Chem, 292, pp.3900~3908 (2017)
49. Lee, C. H., "IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions", Nat. Immunol, 18, pp.889~898 (2017)
50. Wang, P., "Peptide binding predictions for HLA DR, DP and DQ molecules", BMC Bioinform, 11, pp.568~ (2010)
51. Fleri, W., "The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design", Front. immunol, 8, pp.278~ (2017)
52. Marques-Mejías, M. A., "Lymphocyte transformation test (LTT) in allergy to benznidazole: a promising approach", Front. immunol, 10, pp.469~ (2019)
53. Borrok, M. J., "pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling", J. Biol. Chem, 290, pp.4282~4290 (2015)
54. Ju, M. S., "Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding", Mol. Immunol, 67, pp.350~356 (2015)
55. Lu, J., "Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding", Proc. Natl Acad. Sci. USA, 112, pp.833~838 (2015)
56. Duncan, A. R., "The binding site for C1q on IgG", Nature, 332, pp.738~740 (1988)
57. Majumdar, R., "Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum halflife", MAbs, 7, pp.84~95 (2015)
58. Schäfer, A., "Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo", J. Exp. Med, 218, pp.e20201993~ (2021)
59. Winkler, E. S., "Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection", Cell, 184, pp.1804~1820.e1816 (2021)
60. Bournazos, S., "Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity", Cell, 158, pp.1243~1253 (2014)

관련 논문AI추천